Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardiff Oncology, Inc. (Nasdaq: CRDF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on PLK1 inhibition and its lead asset onvansertib, Cardiff Oncology uses filings such as Forms 10-K, 10-Q and 8-K to report its financial condition, clinical development progress and material corporate events.
In recent Form 8-K filings, Cardiff Oncology has furnished press releases covering quarterly financial results, business updates and positive data from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. These filings also reference presentation materials for clinical data updates and summarize key milestones in the onvansertib program. Other 8-Ks document outcomes of the annual meeting of stockholders, including director elections, auditor ratification, equity plan amendments and advisory votes on executive compensation.
Through its periodic reports, such as Form 10-K and Form 10-Q, Cardiff Oncology discusses research and development expenses, royalty revenues, cash and investment balances, and risk factors associated with clinical-stage oncology drug development. These documents outline the company’s dependence on successful clinical trials, regulatory approvals and access to capital, as well as competitive and operational risks.
On Stock Titan, each filing is accompanied by AI-powered summaries that highlight the most important points, helping readers quickly understand complex financial tables, clinical program descriptions and legal language. Users can follow new filings in near real time as they are posted to EDGAR and use this page to review Cardiff Oncology’s historical regulatory record, including information relevant to governance, compensation, capital structure and the progress of onvansertib across multiple cancer indications.
Cardiff Oncology is asking stockholders to vote at its June 11, 2026 annual meeting on four main items: electing six directors, ratifying BDO USA as auditor, expanding the 2021 Omnibus Equity Incentive Plan, and approving executive pay on an advisory basis.
The equity plan share reserve would increase by 3,000,000 shares, bringing total issuable shares to 15,150,000, compared with 68,369,896 common shares outstanding as of April 20, 2026. The company highlights recent equity burn and overhang levels and positions the request as competitive within life sciences peers.
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner filed an initial statement of beneficial ownership, reporting direct holdings of 500 shares of Common Stock. This Form 3 reflects his existing ownership position and does not show any reported purchases, sales, or option exercises.
Cardiff Oncology, Inc. reported that Chief Financial Officer Joshua B. Muntner received a grant of 486,650 stock options to purchase common stock at an exercise price of $1.58 per share. These options expire on April 6, 2036 and are held directly.
According to the vesting schedule, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months after that date. Following this award, Muntner holds a total of 487,150 stock options linked to Cardiff Oncology common stock.
Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share. These options were awarded as compensation, not purchased in the open market, and expire on April 14, 2036.
Following this grant, Smeal holds stock options for 1,279,805 shares in total. The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly for 36 months thereafter, creating a multi‑year retention and incentive structure.
Cardiff Oncology, Inc. Chief Financial Officer Joshua B. Muntner reported a compensation-related grant of 486,650 stock options on April 6, 2026. These options allow him to purchase common stock at an exercise price of $1.58 per share and expire on April 6, 2036.
According to the vesting terms, 121,663 options vest on April 6, 2027, and 10,139 options vest monthly for 36 months thereafter. Following the grant, he holds 487,150 stock options and 500 shares of common stock, all reported as directly owned.
Cardiff Oncology is reshaping its leadership team, naming board member and Interim CEO Mani Mohindru, Ph.D., as President and Chief Executive Officer. She receives a base salary of $655,000, a $100,000 bonus and a 55% annual discretionary bonus, plus incentive stock options totaling 800,000 shares with exercise prices of $1.56 and $1.62 per share, vesting over four years.
The company appointed Josh Muntner as Chief Financial Officer effective April 6, 2026, with a $475,000 base salary, 40% annual discretionary bonus and a non-qualified inducement option to purchase 486,650 shares at $1.58 per share, vesting over four years. Ajay Aggarwal, MD, MBA, will become Chief Operating Officer on April 27, 2026, with a $490,000 base salary, 40% annual discretionary bonus and an expected grant of 400,000 stock options.
Cardiff Oncology highlights that there are no special arrangements or family relationships involved in these appointments. The company continues to advance its lead PLK1 inhibitor, onvansertib, in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer and other PLK1-driven tumors.
Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock. These options have an exercise price of $1.62 per share and expire on March 31, 2036.
The grant is compensation-related, not an open-market trade. Following this award, the filing shows option holdings of 968,766 stock options. A footnote states that 150,000 options vest on March 31, 2027, with 12,500 options vesting monthly for 36 months thereafter, creating a multi-year vesting schedule.
Cardiff Oncology, Inc. entered into separation agreements on March 27, 2026 with former CEO Dr. Mark Erlander and former CFO James Levine, who had previously stepped down as part of a strategic review.
Dr. Erlander will receive his $635,000 base salary paid over 12 months from the separation date, his 2025 bonus of $122,238, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. He also signed a consulting agreement, and his stock options will continue to vest until June 2026, after which vested options are exercisable for 12 months.
Mr. Levine will receive his $490,000 base salary paid over 12 months, his 2025 bonus of $61,740, 50% of his 2026 target bonus prorated over 12 months, and up to 12 months of continued healthcare benefits. His vested stock options are exercisable for 12 months after the separation date. Both executives agreed to a general release and confidentiality, and on March 27, 2026, Dr. Erlander also resigned as a director.
Cardiff Oncology Inc: Ownership update by The Vanguard Group. The filing amends a Schedule 13G to report 0 shares beneficially owned, representing 0% of Common Stock as of the report. The filing notes an internal realignment at The Vanguard Group, Inc. effective January 12, 2026, with certain subsidiaries now reporting separately.